The Effectiveness of HESA-A Supplement Combined with Atorvastatin on Nonalcoholic Fatty Liver in Rats

Publish Year: 1396
نوع سند: مقاله ژورنالی
زبان: English
View: 159

This Paper With 13 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_ZUMS-25-110_006

تاریخ نمایه سازی: 11 اردیبهشت 1400

Abstract:

Background and Objective: Fatty liver disease occurs due to disturbances in lipid metabolism (increased fat synthesis and halting of catabolism) which eventually leads to the accumulation of large amounts of fat (triglycerides) in liver cells, that if left untreated lead to inflammation and cirrhosis. This study aimed to investigate the effect of concomitant use of HESA-A and atorvastatin on biochemical parameters in non-alcoholic fatty liver disease compared with atorvastatin alone. Methods and Materials: ۲۸ rats weighing ۱۸۰±۲۰ g were randomly divided into two groups: a control group (n = ۷) with standard diet and a HFD (high-fat diet) group (n=۲۱) which were fed for ۸ weeks. To confirm the induction of fatty liver; controls along with seven rats from the HFD group were killed. The remaining ۱۴ animals were divided into two groups. The first group received atorvastatin and the second group received HESA-A in combination with atorvastatin daily for ۳۰ days. Finally, biochemical parameters (glucose, lipid profile and liver enzymes) were measured and histological studies were performed on the liver samples. Results: Biochemical parameters in the HESA-A combined with atorvastatin group were significantly decreased in comparison to the atorvastatin group (p<۰.۰۱). The histopathological study of liver tissue showed a significant reduction in the amount of fat tissue and conversion of fatty liver from grade ІІІ to grade І. Conclusion: According to the results of this study, the use of HESA-A as a complementary treatment for fatty liver disease without side effects can be integral role in reducing the incidence of non-alcoholic fatty liver disease, especially in severe cases.

Authors

مجید عفتی

Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

محمود خرمی

Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

علی زارعی محمودی آبادی

Dept of Clinical Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

جواد رئوف سر شوری

Dept. of Anatomy, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • References1- Duan X-Y, Qiao L, Fan J-G. Clinical features of ...
  • Sherlock S, Dooley J. Diseases of the liver and biliary ...
  • Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of ...
  • Lankarani KB, Ghaffarpasand F, Mahmoodi M, et al. Non alcoholic ...
  • Targher G, Bertolini L, Padovani R, et al. Prevalence of ...
  • Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, ...
  • Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of ...
  • Farrell GC, George J, de la M. Hall P, McCullough ...
  • to NASH and related fatty liver disorders fatty liver disease. ...
  • Hamaguchi M, Kojima T, Takeda N, et al. The metabolic ...
  • Valenti L, Dongiovanni P, Piperno A, et al. Alpha 1-antitrypsin ...
  • Musso G, Gambino R, De Michieli F, et al. Dietary ...
  • Assy N, Nasser G, Kamayse I, et al. Soft drink ...
  • Inokuchi-Shimizu S, Park EJ, Roh YS, et al. TAK1-mediated autophagy ...
  • Moallem S, Ahmadi A, Moshafi M, Taghavi M. Teratogenic effects ...
  • Moallem SA, Ahmadi A, Niapour M, Hosseini T, Habibi G. ...
  • Sadeghi-Aliabadi H, Ahmadi A. Cytotoxicity and antitumor properties of a ...
  • Naseri M, Rezaeizadeh H, Asghari M, et al. The effect ...
  • 23-30 ...
  • Ahmadi A, Naderi G, Asgary S. Evaluation of hepatoprotective potential ...
  • Rouhollah V, SeyedMehdi S, Rezvan Z, et al. In vitro ...
  • Mehdipour M, Taghavi Zenouz A, Mesgari Abbasi M, et al. ...
  • Ghasemi M, Nadali F, Ostad SN, Zaker F, Rostamy S, ...
  • Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: ...
  • Ji G, Zhao X, Leng L, Liu P, Jiang Z. ...
  • Wang JQ, Li J, Zou YH, et al. Preventive effects ...
  • Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon ...
  • Nakhjavani M, Khalilzadeh O, Khajeali L, et al. Serum oxidized-LDL ...
  • Chidambaram J, Venkatraman AC. Cissus quadrangularis stem alleviates insulin resistance, ...
  • Angulo P. Nonalcoholic fatty liver disease. New England J Medicine. ...
  • Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis ...
  • Riahi S, Mohammadi MT, Sobhani V, Soleimany M. Chronic effects ...
  • Ahmadi A, Mohagheghi M, Karimi M, Seyed Ali G, Naseri ...
  • Talebi Pour B, Jameshorani M, Salmani R, Chiti H. The ...
  • نمایش کامل مراجع